Evaluation of BTX Injections in Treatment of Bruxism
Status:
Not yet recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
Aim of this study is to evaluate the effect of botulinum toxin type A (Xeomin®) on patients
complaining from bruxism.
The study will be a one arm clinical trial. Twelve subjects reporting bruxism irresponsive to
conventional treatment modalities will be recruited and will be injected with botulinum toxin
A (Xeomin®) in both masseter and temporalis muscles. Pain levels, Electromyographic activity
and maximum occlusal force will be recorded in the subjects before injection and at 1 and 3
months after injection to determine the effect of treatment